Professor Yair Reisner

Chief Scientific Consultant

Professor Reisner is a Professor of Immunology and has served as Head of both the Immunology Department and the Center for Transplantation Biology Research at the Weizmann Institute of Science, Israel’s leading academic research institution and among the top institutions in the world. He holds a M.Sc. in biochemistry from the University of California at Berkley and a PhD in biophysics from the Weizmann Institute. In New York City he has served as Visiting Professor at Memorial Sloan-Kettering Cancer Center, Columbia University and the Skirball Institute of Biomolecular Medicine, N.Y.U. Medical Center. He was also Visiting Professor at the Dana Farber Cancer Institute at Harvard University and a Schiffer Exchange Visitor at the Samuel Lunenfeld Research Institute, Mount Sinai Hospital in Toronto.

A past President of the Israel Stem Cell Society and member of the review panel for stem cell research in the Scientific and Medical Research Funding Working Group of the California Institute for Regenerative Medicine, he has received awards from the American Society of Hematology, the International Society for Experimental Hematology and the European Bone Marrow Transplantation Society, where he has been a member of the Immunology Working Group for almost two decades. A pioneer in mismatched transplants, he co-authored the book “Bone Marrow Transplantation Across Major Genetic Barriers” (World Scientific, 2011) and is currently the Deputy Editor of Bone Marrow Transplantation Journal.

Dr. Dennis Brown

Chairman of the Board

Dr. Brown is a founder and Chief Scientific Officer and Director of Del Mar Pharmaceuticals. He has over thirty years of drug discovery and development experience and has served as Chairman of Mountain View Pharmaceuticals’ Board of Directors. He founded ChemGenex Therapeutics, which merged with a publicly traded Australian company in 2004 to become ChemGenex Pharmaceuticals (ASX: CXS/NASDAQ: CXSP), of which he served as President and a Director until 2009. ChemGenex was then acquired by US biopharmaceutical company Cephalon, which itself was then acquired by Teva Pharmaceutical Industries in 2011 for $6.8 billion.

Dr. Brown was co-founder of Matrix Pharmaceutical, Inc., where he served as Vice President of Scientific Affairs and later Vice President of Discovery Research. He has served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is also an inventor with 34 US patents and patent applications.

Dr. Terry Strom

Scientific Advisory Board Chairman

Professor of Medicine and Surgery at Harvard Medical School and Director of the Transplant Institute at Beth Israel Deaconess Medical Center. Dr. Strom was the founding President of the American Society of Transplantation, past President of the Clinical Immunology Society and has been awarded life-time achievement awards by the American Society of Transplantation, the American Society of Nephrology and the International Society of Nephrology. He received his undergraduate and medical school education at the University of Illinois.

Throughout a long career in Immunobiology, Dr. Strom's principle interest has been in immune 'tolerance,' particularly in transplantation and diabetes. He is specifically interested in the mechanism of tolerance. He trained in internal medicine at the University of Illinois Hospital and Boston’s then Beth Israel Hospital and in nephrology and transplant immunology at the Peter Bent Brigham (now Brigham and Women’s Hospital). Upon completion of his training, he was appointed Medical Director of the hospital’s transplant program. Dr. Strom moved to Beth Israel Hospital, another Harvard teaching hospital, as Medical Director of their transplant program. His work has been continuously funded by the NIH for over 30 years.

Dr. Herman Waldmann

Scientific Advisory Board

Served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford’s Therapeutic Antibody Centre. Dr. Waldmann gained his BA, MD and PhD at Cambridge, where he was also Professor of Therapeutic Immunology. He is a key figure in the field of immune system regulation. A past winner of the prestigious Starzl Prize in Surgery and Immunology from the Starzl Transplantation Institute at the University of Pittsburg. Dr. Waldmann received a SCRIP Lifetime Achievement Award, one of the most prestigious awards in the biotechnology industry.

Throughout his three decades at Oxford, Dr. Waldmann’s focus has been on regulation of immune response and his current interest is in reprogramming the immune system to accept histoincompatible stem cell-derived transplants. His pioneering work in the use of therapeutic monoclonal antibodies to induce immune tolerance was translated into Lemtrada, a Multiple Sclerosis treatment developed by Genzyme (Sanofi) and approved by the FDA after achieving significantly reduced relapse rates of the disease. Dr. Waldmann has served on multiple advisory boards including the UK Medical Research Council, a UK government agency, the Wellcome Trust, a global charitable organization, and Cancer Research UK, all of which provide major funding of UK biomedical research.

Dr. Steven Burakoff

Scientific Advisory Board

Dr. Steven Burakoff, Director of the Tisch Cancer Institute at Mount Sinai Medical Center and Professor of Cancer Medicine and Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai Center. Dr. Burakoff, who served as a Research Fellow at Harvard Medical School under Professor Benacerraf, a Nobel Laureate in Physiology and Medicine for his work in immunology, went on to become a Professor at Harvard Medical School. At New York University School of Medicine he served as Director of both the Skirball Institute of Biomolecular Medicine and the NYU Cancer Institute and Kaplan Comprehensive Cancer Center before joining Mount Sinai Medical Center.

Dr. Burakoff’s ongoing research focus is on T cell activation, mismatched bone marrow transplantation and translational cancer research. He was Chair of Pediatric Oncology and served on the Executive Committee of the Board of Trustees at the Dana Farber Cancer Institute, Chaired the Advisory Committee on Immunology and Immunotherapy of the American Cancer Society and in 2009 received a Lifetime Achievement Award from the American Association of Immunologists. Dr. Burakoff has served as a consultant to Novartis, Bristol Myers Squibb and Hoffman Laroche and was on the Board of Directors of Genzyme Corporation when it was acquired by Sanofi-Aventis in 2011 for over $20 billion.

Dr. Robert Negrin

Scientific Advisory Board

Director of the Bone and Marrow Transplantation Division and Professor of Medicine at Stanford University. Dr. Negrin received his medical degree at Harvard Medical School and training in Internal Medicine and Hematology at Stanford University. He is the Program Leader of the Immunology and Immunotherapy of Cancer Program at the Stanford University Cancer Center. He is currently an Associate Editor of Blood (the weekly journal of the American Society of Hematology) and has served on the editorial boards of the Journal of Clinical Oncology and Biology of Blood and Marrow Transplantation.

Having taught at Stanford for 25 years, Dr. Negrin has spent the past decade focusing on the use of T cells in immunotherapy. He has served as the President of the American Society of Bone and Marrow Transplantation and the International Society of Cellular Therapy. He is an elected member of the Association of American Physicians. Dr. Negrin has earned research awards from the National Institutes of Health, the Leukemia Society of America and the Jose Carerras Leukemia Foundation and was a Doris Duke Distinguished Clinical Scientist Awardee.

Dr. Hermann Einsele

Scientific Advisory Board

Professor of Internal Medicine and Director of the Department of Internal Medicine of the Julius Maximilian University, Würzburg, Germany. Dr. Einsele trained in Germany and the UK, and was a Research Fellow in the Department of Hematology, Oncology, Rheumatology, and Immunology at the University of Tübingen, Germany. A former visiting professor at both the Fred Hutchinson Cancer Research Center in Seattle, WA and at the City of Hope Hospital in Duarte, CA, Professor Einsele is a member of the American Society of Hematology (ASH) as well as the European Hematology Association (EHA).

Dr. Einsele is the Chairman of the German Study Group on Multiple Myeloma and serves on the Board of Directors of both the German Society of Blood and Marrow Stem Cell Transplantation and the German Lymphoma Group. He is part of the working group for Infectious Disease, Chronic Leukemia and Immunobiology at the European Group for Blood and Marrow Transplantation (EBMT). A past recipient of the van Bekkum Award, the highest annual European award for research in the field of stem cell transplantation, he is an Honorary Fellow of the Royal College of Pathologists (London), and was the 2012 Nobel Lecturer on Stem Cell Biology/Transplantation at the Nobel Forum, Karolinska Institute (Sweden).

Dr. Michael Farber

Strategic Patent Advisor

Dr. Farber is a Partner with Ditthavong & Steiner P.C. and member of their Intellectual Property Practice involving patents, trademarks, and copyrights. He specializes in biotechnology patent prosecution including genetic engineering, immunochemistry, cellular immunology, monoclonal antibodies and genomics. Over the past four decades, he has served as IP counsel at Catalyst Law Group, Oppenheimer Wolff & Donnelly, Merchant & Gould and Sheldon & Mak.

Dr. Farber started his education at the California Institute of Technology where he earned his B.S. in Biology. He then attended Harvard University where he was awarded a National Institutes of Health Fellowship and then went on to earn his Ph.D. in Biochemistry & Molecular Biology. He earned his J.D. Magna Cum Laude from Southwestern University School of Law in Los Angeles where he received an American Jurisprudence Award. He is the co-author of “The Scope of Patent Protection for Physiologically Important Proteins and Peptides,” Biopharm, 1990.

Itamar Shimrat

Chief Executive Officer, Chief Financial Officer and Director

A Canadian businessman and a founding member of Cell Source. Since Cell Source Israel's inception, Mr. Shimrat served as a Director, Chief Financial Officer and, in October 2013, he was appointed Chief Executive Officer. Previously, Mr. Shimrat served as an Executive Vice President and Division Head at First International Bank of Israel (FIBI), where he founded and led the strategic planning function, including planning, strategy, strategic marketing & branding and project management oversight functions. He led a successful rebranding and repositioning of the bank and during his tenure the bank's ROE was doubled.

Previously, Mr. Shimrat worked as an international management consultant, chiefly at McKinsey & Co., and he led successful major profit improvement programs for top tier financial institutions including Barclays in England and the Commonwealth Bank of Australia. He began his management consulting career at Bain & Company, where he participated in the development of a new global retail strategy for Citibank. He holds an MBA with Distinction from the Ivey Business School of the University of Western Ontario in Canada.